

Table S1. Association between Gout at Baseline and Cause-specific Mortality.

	15 year Cumulative Incidence (unadjusted) N with Event (%)		Unadjusted		Adjusted*	
Endpoint	No Gout History	Gout History	HR (95% CI)	p-value	HR (95% CI)	p-value
Fatal MI	239 (1.6)	31 (2.4)	1.57 (1.08,2.29)	0.018	1.00 (0.67,1.50)	0.994
Sudden cardiac death	356 (3.2)	31 (2.9)	1.22 (0.85,1.77)	0.282	0.89 (0.61,1.31)	0.563
Heart failure death	126 (1.0)	19 (1.7)	1.99 (1.23,3.23)	0.005	1.03 (0.61,1.73)	0.9184
Cardiac procedure death	127 (0.8)	14 (1.1)	1.30 (0.75,2.26)	0.350	0.990 (0.56,1.76)	0.973
Other cardiac death	1913 (17.8)	251 (26.2)	1.87 (1.64,2.13)	<.001	1.23 (1.07,1.42)	0.003
Non-cardiac death	3651 (33.7)	362 (40.2)	1.43 (1.29,1.59)	<.001	1.14 (1.02,1.28)	0.021
Unknown cause of death	406 (3.9)	38 (4.9)	1.31 (0.94,1.83)	0.111	0.92 (0.65,1.30)	0.639

CV indicates cardiovascular; MI, myocardial infarction

^{*}Adjusted for age, sex, race, prior medical history (including prior MI, coronary artery bypass grafting, congestive heart failure, congestive heart failure severity class, cerebrovascular disease, peripheral vascular disease, diabetes,

carotid bruits, history of chronic obstructive pulmonary disease, body mass index, congestive heart failure severity class [≤2 weeks pre-cath], history of smoking, ventricular gallup, history of renal disease, baseline estimated glomerular filtration rate [Chronic Kidney Disease Epidemiology Collaboration], any valvular heart disease, hypertension, systolic blood pressure, year of index cath, history of liver disease, number of diseased vessels, left main stenosis ≥50%, acute coronary syndrome status, baseline use of aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or statin therapy).

Table S2. Association between Gout at Baseline OR during Follow-up and Cause-specific Mortality.

Endpoint	Unadjusted	Unadjusted	$\mathbf{Adjusted}^*$	Adjusted*	
	HR (95% CI)	p-value	HR (95% CI)	p-value	
Fatal MI	1.46 (1.01,2.10)	0.042	0.93 (0.631,1.38)	0.726	
Sudden cardiac death	1.45 (1.09,1.95)	0.012	1.10 (0.81,1.50)	0.547	
Heart failure death	3.86 (2.69,5.54)	<.001	2.42 (1.64,3.57)	<.001	
Cardiac procedure death	1.37 (0.81,2.30)	0.240	1.07 (0.62,1.84)	0.810	
Other cardiac death	1.86 (1.66,2.08)	<.001	1.25 (1.11,1.41)	<.001	
Non-cardiac death	1.53 (1.40,1.67)	<.001	1.21 (1.10,1.33)	<.001	
Unknown cause of death	1.514 (1.174,1.954)	0.001	1.03 (0.77,1.36)	0.865	

CV indicates cardiovascular; MI, myocardial infarction

^{*}Adjusted for age, sex, race, prior medical history (including prior MI, coronary artery bypass grafting, congestive heart failure, congestive heart failure severity class, cerebrovascular disease, peripheral vascular disease, diabetes, carotid bruits, history of chronic obstructive pulmonary disease, body mass index, congestive heart failure severity class [≤2 weeks pre-cath], history of smoking, ventricular gallup, history of renal disease, baseline estimated glomerular filtration rate [Chronic Kidney Disease Epidemiology

Collaboration], any valvular heart disease, hypertension, systolic blood pressure, year of index cath, history of liver disease, number of diseased vessels, left main stenosis ≥50%, acute coronary syndrome status, baseline use of aspirin, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or statin therapy).

Figure S1. Cumulative Incidence Curves for CV death by Baseline Gout Status.




Figure S2. Cumulative Incidence Curves for All-cause Mortality by Baseline Gout Status.

